100-day clinical outcomes
| . | . | . | . | P* . | |
|---|---|---|---|---|---|
| . | Case cohort A . | Control cohort B . | Control cohort C . | A vs B . | A vs C . |
| Allo-HSCT, % | |||||
| OS (95% CI) | 92 (82, 97) | 94 (85, 98) | 95 (87, 98) | 66 | 53 |
| PFS (95% CI) | 83 (71, 90) | 85 (74, 92) | 80 (69, 88) | 72 | 68 |
| NRM (95% CI) | 7.8 (2.9, 16) | 2.9 (0.5, 9.2) | 2.6 (0.5, 8.3) | 16 | 19 |
| Relapse (95% CI) | 9.4 (3.8, 18) | 11.8 (5.5, 21) | 17 (9.6, 26) | 9 | 38 |
| Auto-HSCT, % | |||||
| OS (95% CI) | 100 (100, 100) | 98 (85, 100) | 98 (88, 100) | 39 | 5 |
| PFS (95% CI) | 97 (83, 100) | 91 (77, 96) | 94 (84, 98) | 2 | 61 |
| IEC, % | |||||
| OS (95% CI) | 92.6 (74, 98) | 91 (74, 97) | † | 78 | † |
| PFS (95% CI) | 70 (49, 84) | 58 (39, 72) | † | 29 | † |
| . | . | . | . | P* . | |
|---|---|---|---|---|---|
| . | Case cohort A . | Control cohort B . | Control cohort C . | A vs B . | A vs C . |
| Allo-HSCT, % | |||||
| OS (95% CI) | 92 (82, 97) | 94 (85, 98) | 95 (87, 98) | 66 | 53 |
| PFS (95% CI) | 83 (71, 90) | 85 (74, 92) | 80 (69, 88) | 72 | 68 |
| NRM (95% CI) | 7.8 (2.9, 16) | 2.9 (0.5, 9.2) | 2.6 (0.5, 8.3) | 16 | 19 |
| Relapse (95% CI) | 9.4 (3.8, 18) | 11.8 (5.5, 21) | 17 (9.6, 26) | 9 | 38 |
| Auto-HSCT, % | |||||
| OS (95% CI) | 100 (100, 100) | 98 (85, 100) | 98 (88, 100) | 39 | 5 |
| PFS (95% CI) | 97 (83, 100) | 91 (77, 96) | 94 (84, 98) | 2 | 61 |
| IEC, % | |||||
| OS (95% CI) | 92.6 (74, 98) | 91 (74, 97) | † | 78 | † |
| PFS (95% CI) | 70 (49, 84) | 58 (39, 72) | † | 29 | † |